Sickle cell disease (SCD) is a monogenic disorder that afflicts approximately 100,000 Americans and millions of people worldwide. It is characterized by hemolytic anemia, vaso-occlusive crises, relentless end-organ injury, and premature death. Currently, red blood cell transfusion and hydroxyurea are the major disease-modifying therapies available for SCD. Hematopoetic stem cell transplant is curative, but barriers to treatment are substantial and include a lack of suitable donors, immunologic transplant rejection, long-term adverse effects, prognostic uncertainty, and poor end-organ function, which is especially problematic for older patients. Gene therapy to correct the b s point mutation is under investigation as another curative modality. Deeper insights into the pathophysiology of SCD have led to the development of novel agents that target cellular adhesion, inflammation, oxidant injury, platelets and/or coagulation, vascular tone, and hemoglobin polymerization. These agents are in preclinical and clinical trials. One such agent, L-glutamine, decreases red blood cell oxidant injury and is recently US Food and Drug Administration approved to prevent acute pain episodes of SCD in patients 5 years of age or older. The purpose of this review is to describe the currently established therapies, barriers to curative therapies, and novel therapeutic agents that can target sickle cell hemoglobin polymerization and/or its downstream sequelae. A PubMed search was conducted for articles published up to May 15, 2018, using the search terms sickle cell disease, novel treatments, hematopoietic stem cell transplantation, and gene therapy. Studies cited include case series, retrospective studies, prospective clinical trials, meta-analyses, online abstracts, and original reviews.
F or this review, we conducted a PubMed search for articles published up to May 15, 2018 , using the search terms sickle cell disease, novel treatments, hematopoietic stem cell transplantation, and gene therapy. Studies cited include case series, retrospective studies, prospective clinical trials, meta-analyses, online abstracts, and original reviews.
Sickle cell disease (SCD), described as the "first molecular disease" in 1949, 1 comprises congenital hemolytic anemias caused by the inheritance of point mutations in the b-globin allele. Sickle cell disease is an umbrella term that includes homozygous sickle cell anemia (SCA), which is defined by the exclusive production of hemoglobin Life expectancy is shortest for people with HbSS and HbSb 0 who are at greater risk for central nervous system complications, nephropathy, and early death than people with compound heterozygous SCD. 2, 3 Across genotypes, clinical phenotype is improved by the presence of high HbF levels and/or coinheritance of the a-thalassemia trait. 4, 5 PATHOPHYSIOLOGY Multiple pathophysiologic mechanisms contribute to the clinical manifestations of SCD. Under conditions of low oxygen tension, HbS polymerizes in red blood cells (RBCs) and forms elongated rods that alter RBC rheology. Hemoglobin S polymerization is initially reversible, but repeated deoxygenation/reoxygenation cycles cause RBC surface property changes, membrane damage, and hemolysis. Altered RBC conformation leads to vasoocclusion, ischemia, and inflammation. [6] [7] [8] [9] Hemoglobin Secontaining reticulocytes are more adherent and may trap older misshapen RBCs in postcapillary venules, where oxygen tension is lower. 10 Pathologic interactions between the vascular endothelium, leukocytes, and platelets also contribute to SCD pathology. 6, 11 Increased endothelial E-and P-selectin activity, 8 RBC intercellular adhesion molecule 4 and basal cell adhesion molecule/ Lutheran activity, 8, 12, 13 leukocyte adhesion, 14 platelet activation, [15] [16] [17] [18] [19] and nitric oxide (NO) depletion [20] [21] [22] contribute to acute and chronic vascular injury and pain ( Figure 1 ). Ongoing drug development efforts target these mechanisms.
EPIDEMIOLOGY AND CLINICAL COMPLICATIONS
In the United States, 90,000 to 100,000 people have SCD, 23 and survival into adulthood is nearly universal. 24 Improved survival is a consequence of 6 decades of progress in the field. Common diagnostic, prevention, and treatment strategies responsible for these advances include newborn screening, penicillin prophylaxis, 25 vaccinations against encapsulated organisms, transcranial Doppler (TCD) screening (to identify and then treat children at risk of stroke with transfusions), 26, 27 and aggressive, intensive hospital-based care. For patients with HbSS and HbSb 0 , early initiation of hydroxyurea has also contributed to decreased symptom burden and is associated with increased longevity. 28 In resource-rich countries, the burden of morbidity and mortality from chronic end-organ damage has shifted into adulthood.
Globally, nearly two-thirds of infants with HbSS are born in Nigeria, the Republic of Congo, or India, where childhood mortality remains high. 29 By 2050, the increased use of newborn screening and penicillin prophylaxis and vaccination in developing countries may prevent up to 5 million deaths in children with SCD. 29 In 2010, the number of newborns with homozygous SCD worldwide was 305,800. By 2050, it will be approximately 400,000. 29 This expanding and aging population of people with SCD is likely to place major demands on global health care resources if they experience the protean clinical manifestations of SCD.
Sickle cell disease complications are acute and chronic. Acute complications include pain crises, acute chest syndrome, stroke, and hepatic or splenic sequestration. Common sites of chronic injury are the brain, eyes, heart, kidneys, lungs, and liver. These complications require intensive outpatient, inpatient, and emergency department care. Unfortunately, despite considerable need, few curative therapies or disease-modifying agents that target the underlying pathobiology in SCD exist.
Hydroxyurea and long-term treatment with blood transfusions are the only disease modifying therapies that prevent and treat acute and chronic complications in SCD. Allogeneic hematopoietic stem cell transplant (HSCT) is the only cure, and gene therapy is under investigation as a potential curative strategy. Further advances in our understanding of the underlying pathophysiology of SCD contribute to the development of exciting and novel targeted therapies to prevent and treat SCD complications. Drugs that inhibit cellular adhesion, reduce oxidative injury, membrane damage, and hemolysis, or increase NO bioavailability are in clinical trials, 30 as are novel gene-editing strategies that incorporate autologous stem cell modification and transplant.
In this review, we discuss established and developing treatments for SCD (Table) and classify them on the basis of their mechanism of action ( Figure 2 ). Therapies that decrease HbS polymerization are discussed first, followed by those that target the downstream effects of HbS polymerization.
REDUCTION OF HBS POLYMER FORMATION AND CORRECTING THE MOLECULAR DEFECT Hydroxyurea
Hydroxyurea was the first US Food and Drug Administration (FDA)eapproved drug for the treatment of homozygous SCD and is the only disease-modifying therapy that is supported by robust evidence in children and adults. Hydroxyurea is a ribonucleoside diphosphate reductase inhibitor first used as cytoreductive therapy for myeloproliferative diseases. Hydroxyurea increases fetal Hb (HbF; a2g2) production and decreases intracellular HbS polymerization, an effect that is sustained with long-term use but is reversible on drug discontinuation. 31 The discovery that hydroxyurea increases HbF levels led to initial trials of the drug in patients with HbSS. 32, 33 Secondary cellular benefits from hydroxyurea for patients with homozygous SCD include decreasing leukocyte, platelet, and reticulocyte counts and changes in cellular, inflammatory, and adhesion molecule expression that reduce pathologic cellular adhesion and inflammation. [34] [35] [36] Studies in adults and children supporting the use of hydroxyurea in homozygous SCD led to the FDA's approval of hydroxyurea for adults nearly 20 years ago and for children in 2017. The 1995 Multicenter Study of Hydroxyurea (MSH) was a randomized, placebo-controlled trial of hydroxyurea in adults with HbSS. In the MSH, those treated with hydroxyurea had fewer painful crises and acute chest syndromes (2.5 vs 4.5 crises per year and 25 vs 51, respectively; P<.001), required fewer blood transfusions (used in 48 vs 73 patients; P¼.001), and experienced less overall long-term mortality (40% reduction; P¼.04) compared with control patients who received placebo. 37, 38 Based on the results of the MSH, the FDA approved hydroxyurea for adults with HbSS disease.
The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) was a phase 3 multicenter placebo-controlled trial of hydroxyurea for infants (9-18 months) with HbSS. BABY HUG did not meet its primary end points: there was no difference in splenic or renal function in children treated with placebo vs hydroxyurea. However, hydroxyurea significantly decreased painful crises, dactylitis, and the frequency and duration of hospitalization, without resulting in significant toxicity. 31, [39] [40] [41] [42] Previously, data for children older than 18 months had been limited to observational studies that supported the long-term use of hydroxyurea in this age group. 43 However, recent observational and randomized data have emerged that strongly encourage the use of hydroxyurea in children. [44] [45] [46] [47] According to the 2014 National Heart, Lung, and Blood Institute guidelines, hydroxyurea should be initiated in adults with severe disease (3 painful crisis per year, history of severe or recurrent SCA, or with symptomatic chronic anemia/pain affecting quality of life) and should be offered to all children with SCA starting at 9 months of age. In the United States, this recommendation appears to be associated with increased hydroxyurea prescribing. 48 Despite increased treatment acceptance, major barriers to implementing hydroxyurea treatment for all eligible patients remain. Prominent barriers include (1) adverse effects such as rash, alopecia, nail discoloration, headache, nausea, and weight gain, unresolved concerns for decreased fertility (especially in males), and teratogenicity [49] [50] [51] ; (2) deciding the optimal timing of treatment initiation in children; in Europe, concerns about unknown and understudied effects of hydroxyurea, including infertility and carcinogenesis, limit hydroxyurea prescribing to children with severe disease 34, [51] [52] [53] ; (3) prescriber discomfort and delay in initiating therapy for eligible patients 54 ; (4) poor patient adherence to a lifelong regimen 34 ; and (5) lack of high-quality evidence for use in patients with variant SCD (compound heterozygotes) who comprise one-third of all patients with SCD. 55 Of note, worries about carcinogenesis from hydroxyurea arose in patients treated for myeloproliferative neoplasms, 52 which have a baseline increased risk of hematologic malignancy. The association of carcinogenesis with hydroxyurea is not substantiated by the available literature. One study found a 2-fold increased age-related risk of leukemia in patients with SCD in California compared with the general population, irrespective of treatment. 56 This finding may reflect the natural history of SCD in the emerging population of older adults with SCD. Long-term followup of patients initiating hydroxyurea in childhood may help clarify whether concerns about hydroxyurea's carcinogenic potential are warranted. 31, 57 Ultimately, hydroxyurea is not a panacea for people with HbSS. Damage to the kidney, 58 brain, 59 and spleen 60 is not entirely prevented with treatment.
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Novel Antisickling Agents
Hemoglobin S polymerization is the first step in the cascading pathophysiology of SCD. Hemoglobin S polymerization is inhibited by agents that (1) induce HbF (eg, hydroxyurea [discussed previously], decitabine, pomalidomide, panobinostat, INCB059872, and sodium butyrate), (2) disfavor polymerization by preventing dehydration (senicapoc and magnesium), (3) delay production of deoxyhemoglobin S by shifting the oxyhemoglobin dissociation curve to the left (increasing affinity of Hb for oxygen, eg, Aes-103 and GBT440), (4) deliver carbon monoxide to the RBC (pegylated carboxyhemoglobin), 61 and (5) inhibit sickling via an unknown mechanism (SCD-101 and Nicosan). SCD-101, a novel botanical drug whose mechanism is unknown, has a dose-dependent antisickling effect. In a phase 1b dose-escalation study in patients with SCA, SCD-101 was tolerated well and decreased chronic pain and fatigue. 62 Part B of this phase 1b clinical trial is a randomized, double blind, placebo-controlled crossover study of SCD-101 in patients with SCA and is currently recruiting (NCT02380079). Another antisickling agent with an unknown mechanism of action, Nicosan (or Niprisan) is a plant extract shown to decrease painful crises in Nigerian patients. 63, 64 There are no trials studying Niprisan in the United States. Clinical trials investigating the use of the aforementioned agents are enrolling patients (Table) .
Long-term Transfusion Therapy
Long-term therapy with RBC transfusion is an alternative to hydroxyurea. Strong evidence guides the use of long-term RBC transfusions for children with HbSS and abnormal to prevent stroke. 26, 27 The multicentered Stroke Prevention Trials in Sickle Cell Anemia (STOP I and II) trials reported that longterm transfusion therapy in children with abnormal TCD reduced stroke risk and that this salutary effect was lost when transfusions were stopped. 26, 27 The Stroke With Transfusions Changing to Hydroxyurea (TWITCH) trial found that transitioning from long-term transfusion therapy to hydroxyurea, at the maximum tolerated dose in children with abnormal TCD but no severe vasculopathy, was noninferior to long-term transfusions in children and could be used as an alternative to transfusions for primary prevention of cerebrovascular disease. 65 Long-term transfusion therapy is performed as simple transfusions or partial or complete exchange transfusions (erythrocytapheresis). Risks of long-term transfusion therapy include transfusional iron overload (less so with exchange transfusions), which accumulates over time and can be life-threatening, alloimmunization, and transmission of transfusion-associated infections. [66] [67] [68] [69] [70] [71] Delayed hemolytic transfusion reactions secondary to alloimmunization complicate 4% to 11% of transfusions for SCD. 67, 72 Stem Cell Replacement/Modification Therapies Hematopoietic Stem Cell Transplant. Allogeneic HSCT cures SCD by eliminating sickle Hb production by replacing existing hematopoetic stem cells with cells from an allogeneic donor. Hematopoietic stem cell transplant is used when the benefits of cure outweigh the risks of transplant-associated toxicities and when a suitable donor is available. Benefits of HSCT include the physiologic normal erythropoiesis, prevention of end-organ damage, and decreased SCD-associated morbidity and mortality. 73 Concerns about HSCT include patient selection (based on age, disease severity, and end-organ injury), risk of short-term toxicity (infection, posterior reversible encephalopathy syndrome, death), graft failure, possibility of long-term adverse effects (graft-vs-host disease [GVHD], infertility), selection of an effective and minimally toxic preparative regimen (myeloablative vs nonmyeloablative), and a limited donor pool. [73] [74] [75] Defining eligibility for HSCT is challenging and is based on individualized analysis of benefits and risks. Age is a strong determinant of successful HSCT. In pediatric patients, matched sibling donor transplants with myeloablative regimens have been successful. 76, 77 Among 1000 HLAidentical sibling HSCT recipients from a worldwide cohort, age was a significant risk factor for mortality. The overall survival of patients older than 16 years was 80% compared with 95% 5-year overall survival in those younger than 16 years (P<.001). 78 Tools to predict SCD severity to determine transplant eligibility are limited and predominantly include major SCD complications. 79 In 2014, an international expert panel recommended that HSCT with unrelated or haploidentical grafts in a controlled trial setting be considered for patients with severe complications of SCD, including stroke, recurrent vasoocclusive crisis (>2 episodes per year), recurrent priapism, impaired neuropsychological function, stage I or II sickle cell lung disease, 80 acute chest syndrome, sickle nephropathy, bilateral proliferative retinopathy, osteonecrosis, or transfusionrelated alloimmunization. 81 The panel also recommended that symptomatic patients be offered transplant from available HLA-identical sibling stem cells or HLA-identical sibling cord blood as early as preschool age. 81 The availability of a suitable donor is a prerequisite to HSCT for transplant-eligible patients and a major barrier to treatment. Only 10% to 20% of patients with SCD in the United States have a matched sibling, matched unrelated donor, or preserved cord bloods available. 74 Thus, recent approaches to HSCT focus on expanding the donor pool by using matched unrelated donors and haploidentical donors. [82] [83] [84] In children, matched unrelated donor recipients have lower 1-and 2-year event-free survival of 76% and 69%, respectively, and lower corresponding overall survival of 86% and 79%. 82, 85 In a pilot multicenter study (STRIDE [Study of Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease]), related and unrelated donor HSCT with a reduced toxicity conditioning regimen in 22 adults with severe SCD, 1-year event-free and overall survival were higher at 95%, without any graft failure and very low rates of GVHD (2 patients with acute grade 1 skin GVHD and 3 with chronic GVHD). 86 At present, cord blood donors are too risky for use in SCD (SCURT [Sickle Cell Unrelated Donor Transplant Trial] study). 87, 88 Haploidentical HSCT is experimental in children and adultsdBMT CTN 1507 (NCT03263559) and National Heart, Lung, and Blood Institute intramural 17-H-0069 (NCT03077542) are 2 trials investigating nonmyeloablative preparative regimens with bone marrow or peripheral blood stem cell grafts, respectively. 89 Haploidentical HSCT is associated with higher transplant morbidity and graft failure, but this approach continues to be pursued because of the potential to considerably expand the donor pool. 78, 83 Children undergoing matched sibling transplants tolerate myeloablative regimens well. 76, 77 In adults, myeloablative regimen toxicity may be prohibitive and needs further study. Although reduced-intensity nonmyeloablative HSCTs were initially associated with only transient donor engraftment, 84 long-term engraftment with a stable mixed-and full-donor chimerism has improved in subsequent studies (2014 National Institutes of Health study and STRIDE, respectively). 86, 90 Both myeloblative (NCT02675959, NCT01590628, and NCT02179359) and nonmyeloablative (NCT01499888, NCT01850108, and NCT03249831) strategies to restore either normal or partial erythropoiesis, respectively, are under investigation at a number of sites. 90 Major concerns about HSCT remain. Whether HSCT prolongs life for patients with SCD is unclear. 91 In a Belgian cohort, survival in adults and children treated with hydroxyurea was superior to those treated with HSCT. 91 Optimization of nonmyeloablative strategies and strategies to expand the donor pool may increase the availability of HSCT; routine reassessments of a patient's baseline SCD and the risks of HSCT are thereby necessary. 79 Infertility is a risk for all patients undergoing HSCT. 92 Fertility preservation, even for very young children, should be offered before treatment. Finally, recommendations for asymptomatic patients and those with compound heterozygosity have not been made. 73 Gene Therapy. Gene therapy is the "Holy Grail" of SCD treatment and has long been sought as a definitive cure. In 2017, Ribeil et al 93 reported that a 13-year-old boy with HbSS disease had been cured with gene therapy. This thrilling event marked the first time an antisickling b-globin variant (bA-T87Q) had been successfully transferred into a human patient. Recent technological breakthroughs, such as in situ gene mutagenesis (eg, via CRISPR/ Cas9), are creating opportunities for genetic manipulation (gene insertion, deletion, or modification) by deleting the HbS mutation or increasing HbF production through silencing a repressor of HbF production (eg, BCL11A).
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After encouraging mouse studies of gene therapy, 96 ,97 2 clinical trials studying gene therapy using a lentiviral vector in adults with homozygous or severe variant SCD are under way (NCT02247843, NCT02186418). More studies are needed to establish this therapy's durability and safety. A myeloablative conditioning regimen followed by the infusion of manipulated autologous stem cells is under investigation. 98 A major advantage of gene therapy over HSCT is the ability to use autologous stem cells, thus obviating the need to identify donors. However, like HSCT, undergoing gene therapy requires exposure to radiation and chemotherapy. Lentiviral transfer has not been associated with insertional carcinogenesis or mutagenesis to date, 99,100 but long-term studies are needed to adequately assess this risk.
TARGETING DOWNSTREAM CONSE-QUENCES OF HBS POLYMERIZATION
Antioxidant Therapy L-glutamine. L-glutamine is an amino acid precursor for nicotinamide adenine dinucleotide (NAD) and is required for the formation of the antioxidant reduced NAD (Figure 3 ). Nicotinamide adenine dinucleotide production is adequate in patients with SCD, but erythrocyte glutathione and glutamine levels are significantly depleted. 101, 102 This decrease has been attributed to the increased oxidant burden in sickle RBCs and higher L-glutamine consumption. 103 Decreased L-glutamine levels lead to lower NAD redox potential and impair erythrocyte integrity, increase hemolysis, and deplete NO. Glutamine depletion is a biomarker for hemolysis and is independently associated with pulmonary hypertension in patients with SCA. 101 The effect of L-glutamine in SCD has been studied, but to validate its benefits and feasibility in age-and genotype-specific populations, additional peer-reviewed evidence is needed. In a prospective interventional study of 7 adults with SCA, L-glutamine powder supplementation for 4 weeks resulted in increased RBC reducing potential and subjective improvement in energy levels. 104 In 2005, a cross-sectional and prospective study of 9 adults with SCA found that L-glutamine supplementation led to diminished adhesion of treated RBCs to human umbilical vein endothelial cells. 104, 105 In 2014, a 2:1 randomized, placebo-controlled, double-blind phase 3 study of L-glutamine oral powder in 230 patients (5-58 years of age) with HbSS and HbS b 0 thalassemia was conducted. 106 Results of this trial have not yet been published in a peerreviewed journal. Data available on the FDA website show that patients receiving L-glutamine had fewer painful events over the 48-week study period (3 events vs 4 events; P¼.008), lower incidence of hospitalization (2 events vs 3 events; P¼.005), a decreased duration of hospital stay (6.5 days vs 11 days; P¼.022), decreased development of acute chest syndrome (11.9% vs 26.9%; P¼.006), and a lengthened median time from randomization to first crisis (87 days vs 54 days; P¼.01). Treatment effect was independent of hydroxyurea use. 107 These data formed the basis for FDA approval in patients with SCD aged 5 years and older. Although L-glutamine is approved for all SCD types, the phase 3 study included only patients with HbSS. Genotype-specific subgroup analyses are not yet available, nor are estimates of cost or feasibility. N-acetylcysteine. N-acetylcysteine (NAC) is an antioxidant used as a mucolytic for respiratory diseases that decreases dense cell and irreversibly sickled cell formation in patients with homozygous SCD.
108 N-acetylcysteine is converted to L-cysteine in the cytoplasm, which increases glutathione levels. In a phase 2 study of 21 patients with SCA who were older than 15 years, NAC restored glutathione levels, decreased dense cell formation, and led to a statistically insignificant decrease in the number of painful crises. 109 A pilot study is currently enrolling participants with HbSS to evaluate the effects of intravenous NAC on plasma von Willebrand factor parameters, redox, and RBC function (NCT01800526).
a-Lipoic Acid and L-acetylcarnitine. A combination of potent antioxidants, a-lipoic acid and acetyl-L-carnitine, was given to 14 patients with hemoglobinopathies (11 with SCD and 3 with HbH-Constant Spring) and significantly improved the redox state of glutathione (reduced:oxidized glutathionine) at 3 weeks. 110 A phase 2 study in patients with SCA assessed reduction in oxidant stress and pain crises using these agents (NCT01054768); results are not available yet.
Other Antioxidant Agents. Gum arabic, omega-3 fatty acids, and curcumin are reported to diminish oxidative stress in SCD but have not achieved widespread clinical applicability to date.
111-113
Inhibition of Cellular Adhesion Numerous novel antiadhesive agents that target RBC-endothelial and leukocyte-endothelial interactions are in development.
P-selectin Inhibitors. P-selectin mediates leukocyte and erythrocyte adhesion to the vascular endothelium and contributes to vasoocclusion in patients wth SCD. 30, 114 P-selectin is stored in endothelial cell granules and is released to the cell surface when stimulated by histamine, thrombin, endotoxin, peroxides, or hypoxia. 6, 114 In a transgenic mouse model expressing human HbS, blocking or depleting P-selectin decreased erythrocyte and leukocyte adhesion. 115, 116 Crizanlizumab (SEG101) is a humanized monoclonal antibody that binds to P-selectin and blocks P-selectin's interaction with P-selectin glycoprotein 1 on circulating leukocytes. The Phase II, Multicenter, Randomized, Placebo-Controlled, 117 There were no differences in hemolytic parameters between the interventional and placebo arms, suggesting that treatment benefit may be attributable only to modified cellular adhesion. The reduction in annual crisis rate was greater in patients not taking hydroxyurea compared with those who were (50% lower vs 32.1% lower, respectively). The SUSTAIN trial included patients aged 16 to 65 years and all SCD genotypes, but 70% of study patients had HbSS. Additional studies are therefore needed to address use in pediatric patients and to assess efficacy by genotype. Adverse events were comparable between treatment and placebo groups.
Pan-selectin Inhibitors. Rivipansel (GMI-1070), a synthetic pan-selectin inhibitor that inhibits cell-cell interactions and adhesion, prolonged survival in Berkeley sickle cell mice 118 and was associated with significant decline in intravenous opioid use (83% lower opioid use compared with placebo) when tested in 73 adults with SCA. 119 A phase 3 trial of rivipansel safety and efficacy is recruiting patients (NCT02187003).
Other Antiadhesive Therapies Intravenous Immunoglobulin. In a sickle cell mouse model, intravenous immunoglobulin inhibited RBC-neutrophil and neutrophilendothelial adhesive interactions and improved microcirculatory blood flow and survival. 120, 121 A phase 2 study is currently recruiting patients to evaluate the safety and efficacy of intravenous immunoglobulin in patients with SCD within 24 hours of admission with a pain crisis (HbSS and HbS b-thalassemia, NCT01757418). Heparin. Heparins are anti-inflammatory and inhibit P-selectinemediated adhesion. 122 A randomized, double-blind trial found that tinzaparin, a low-molecular-weight heparin, reduced the duration of vaso-occlusive crisis without any severe bleeding complications. 123 A feasibility trial is currently recruiting participants to assess the effect of unfractionated heparin in acute chest syndrome (NCT02098993).
Propranolol. In a phase 1 dose-escalation study, propranolol decreased sickle RBC adhesion in a dose-dependent manner when human RBCs from propranolol-treated patients with homozygous SCD were infused into nude mice. 124 Maximum inhibition was achieved at a dose of 40 mg. No significant heart rate changes or severe adverse events were reported. 124 Results from a double-blind crossover phase 2 study (NCT01077921) revealed decreased levels of measured soluble biomarkers including E-selectin, P-selectin, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 in patients with homozygous SCD treated with propranolol compared with placebo, but these decreases were not statistically significant. 125 This study was not published in a peer-reviewed journal. Because of the high prevalence of asthma in children with SCD, a phase 1 study of propranolol in children without asthma was initiated but eventually terminated due to inability to recruit patients (NCT02012777). No studies of propranolol in humans with HbSS are currently open.
Antiplatelet Therapy
Activated platelets are common in SCD and may contribute to vaso-occlusion by participating in intercellular adhesion and forming multicellular aggregates. 126 Prasugrel is a third-generation thienopyridine that inhibits adenosine diphosphateemediated platelet activation and aggregation by irreversibly binding to the P2Y12 class of adenosine diphosphate receptors. The Determining Effects of Platelet Inhibition on Vaso-Occlusive Events (DOVE) trial was a phase 3, double-blind, placebo-controlled study of prasugrel in children and adolescents aged 2 to 17 years with HbSS that did not find a reduced rate of vaso-occlusive crises with prasugrel treatment. 127 In a phase 1 study in patients with SCA, another antiplatelet agent, eptifibatide, a platelet glycoprotein aIIbb3 antagonist, inhibited platelet aggregation and favorably altered inflammatory mediators. 128 A phase 2 placebo-controlled trial reported the safety of eptifibatide in 13 patients with SCD with acute pain crises but did not find improvement in recovery times or time to hospital discharge. 129 A secondary analysis revealed that eptifibatide inhibited platelet aggregation, platelet release, and platelet P-selectin expression and decreased platelet-leukocyte aggregates and inflammatory markers. 130 That antiplatelet agent monotherapy does not benefit patients with SCD suggests that other mechanisms involved in vaso-occlusion may be more prominent drivers of SCD pathophysiology. However, more research with well-powered studies is needed to definitively determine the efficacy of antiplatelet agents for treating or preventing pain.
Agents Affecting Vascular Tone
Intravenous magnesium, inhaled NO, and sildenafil, agents that improve vascular tone and endothelial dysfunction, have not reduced the frequency or duration of painful crises in patients with homozygous and variant SCD. [131] [132] [133] CHALLENGES AND PITFALLS A lack of equitable National Institutes of Health funding 134 and small clinical trials contribute to the limited clinical armamentarium against SCD. Nevertheless, the development of novel treatments for SCD is an area of active research. Current evidence for many therapies is limited by the need for age-and genotype-specific research. The management of SCD is limited by many unanswered clinical questions and challenges, such as (1) treatment options for patients with SCD who are pregnant, 135 (2) the ethical dilemmas posed by the current state of HSCT 136, 137 and gene therapy, especially for asymptomatic patients and (3) optimum pain management in a population faced with lifelong episodes of acute and chronic pain that evolves with age and is exacerbated by socioeconomic stressors and age. 138, 139 Ironically, painda substantial and bedeviling problem for patients, their families, and their physicians alikedis, with few exceptions, 140 seldom specifically targeted in therapeutic trials.
CONCLUSION
Disease-modifying therapies for SCD include hydroxyurea, now FDA approved for adults and children with homozygous SCD, and long-term transfusions. Nearly 2 decades after the approval of hydroxyurea, L-glutamine was FDA approved with little published peerreviewed evidence and many remaining questions about its use and tolerability. Antisickling gene therapy is an exciting and promising area of research but is not yet established as safe or efficacious. Allogeneic HSCT is the only curative treatment and has recently shown promise in older adults as well. Early referral for evaluation for HSCT is strongly encouraged for patients with symptomatic SCD.
There is an unmet need for diseasemodifying therapies in SCD, and a great deal of recent scientific discovery has led to the development and testing of novel agents that are in preclinical and clinical testing. In the coming decades, these new approaches, once optimized, may considerably brighten the outlook for patients with SCD, their families, and their physicians.
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